What Is a Peptidomimetic? Peptides Rebuilt as Drug-Like Molecules

Published October 2026 · Patriot Labs Research Team · ~20 min read

The short answer

A peptidomimetic is a molecule designed to reproduce a peptide’s shape and biological action while shedding the weaknesses that limit peptides — rapid breakdown by enzymes, poor membrane crossing and a short lifetime in solution. It keeps the peptide’s pharmacophore, the arrangement of features a target recognises, but rebuilds the backbone or side chains into something more stable and drug-like.

The idea rests on a distinction between what a peptide is and what it does. What a receptor or enzyme actually reads is a small set of chemical groups held at particular distances and angles — the pharmacophore. The amino-acid chain is just one way to present that pattern, and it happens to be a way that enzymes are very good at dismantling. A peptidomimetic presents the same pattern on different chemistry: it might swap a few bonds, move the side chains, lengthen or stiffen the backbone, or abandon the chain altogether for a rigid scaffold. A standard definition, from a 2008 review, describes a peptidomimetic as a compound whose pharmacophore mimics a natural peptide in three-dimensional space and that retains the ability to produce the same biological effect.^[4]

The rest of this guide works through the main families, from the smallest change — a single altered bond — to the largest, a non-peptide scaffold with no amino acids at all, and then looks at how these molecules are made, how they are characterised, and where the approach has already succeeded. For the natural chemistry these designs depart from, see What Is a Peptide Bond and What Is an Amino Acid.

The problem peptidomimetics solve

Peptidomimetics exist because natural peptides make poor drugs for predictable reasons, and each reason suggests a chemical fix. Peptides are potent and selective, but as molecules they are flexible, fragile and hard to deliver.

Four liabilities recur in the literature. First, proteolysis: the body is full of peptidase enzymes whose job is to cut peptide bonds, so an unmodified peptide is often degraded within minutes. Second, poor membrane permeability: peptides are large and carry many hydrogen-bond donors, which keeps them out of cells and makes oral absorption difficult. Third, rapid clearance and short half-life, which follows partly from the first two. Fourth, conformational flexibility: a floppy chain can adopt many shapes, only one of which binds the intended target, so it may bind other targets as well and dilute both potency and selectivity.^[5][6] Reviews of the field frame peptidomimetic design precisely as a toolbox for addressing these drawbacks while keeping the recognition that made the peptide attractive.^[1][2]

Each fix maps onto a family of modification. Resisting proteases drives bond surrogates, N-methylation and D-amino acids. Improving permeability drives the removal of hydrogen-bond donors and the move to rings and foldamers. Locking a single shape drives cyclisation, stapling and rigid scaffolds. The approaches are complementary, and a real design usually combines several. The specific question of making a peptide last longer is treated in its own right in Peptide Half-Life Extension.

How peptidomimetics are classified

Peptidomimetics are usually classified by how much of the original peptide survives the redesign, running from molecules that are almost entirely peptide to molecules with no amino-acid chain at all. Two schemes are in common use, an older one and a newer one.

The older scheme, associated with Ripka and Rich, sorts mimetics into three types. Type I mimetics reproduce the local topography of the backbone — the arrangement of a particular bond or turn — usually by a direct structural replacement. Type II mimetics are typically small, non-peptide molecules that bind the same site and produce the same functional effect without resembling the peptide at all. Type III mimetics use a novel scaffold to reproduce a whole element of secondary structure, grafting the key side chains onto a rigid framework.^[1]

The newer scheme, introduced by Grossmann and co-workers in 2015, grades mimetics from Class A to Class D by decreasing peptide character.^[3] As summarised in a 2020 tutorial review, Class A involves only minimal, local modification of the sequence; the diagnostic peptide pentagastrin is given as an example. Class B covers larger backbone modifications, including foldamers and peptoids. Class C replaces the backbone with a non-peptide scaffold while keeping the functional groups, as in certain somatostatin and thyrotropin-releasing-hormone analogues. Class D is the least peptide-like, often a molecule arrived at by screening that shares function but little structure with the parent.^[1] The two schemes describe the same continuum from different angles.

Peptide-bond surrogates and isosteres

The most surgical change a peptidomimetic can make is to replace one peptide bond with a different linker that occupies the same space but is not a substrate for peptidases. These replacements are called amide-bond isosteres or surrogates, and they are the building blocks of many Type I mimetics.

An amide bond is planar and offers a hydrogen-bond donor (N–H) and acceptor (C=O); a good isostere keeps as much of that geometry and hydrogen-bonding as the design needs while removing the feature a protease recognises. Reviews list a standard menu: the thioamide (sulfur replacing the carbonyl oxygen), the reduced amide, the (E)-alkene or olefin (which fixes the bond’s geometry rigidly but loses the hydrogen bonding), and the 1,4-disubstituted triazole, a flat ring made by copper-catalysed azide–alkyne “click” chemistry that mimics the amide’s electronics and hydrogen-bonding profile.^[1][2]

A specialised sub-group is the transition-state analogue, used against enzymes that cleave peptide bonds. Here the isostere is designed to resemble not the stable bond but the high-energy intermediate the enzyme forms during catalysis, so it binds far more tightly than the natural substrate. The classic motifs are the hydroxyethylene, hydroxyethylamine, statine (found in the natural inhibitor pepstatin) and ketomethylene groups.^[1] This single idea produced several drug classes, discussed below.

Local backbone edits: N-methylation and D-amino acids

Two of the simplest and most widely used peptidomimetic moves change a residue without abandoning the amide backbone: adding a methyl group to a backbone nitrogen, or replacing an L-amino acid with its mirror image. Both make the chain harder for enzymes to process.

N-methylation puts a methyl group on the backbone nitrogen in place of its hydrogen. That removes a hydrogen-bond donor, restricts the backbone’s rotation, biases it toward turns and cis bonds, and blocks the fit that many proteases require — often improving both stability and membrane permeability at once. The cyclic natural product cyclosporine, with seven N-methyl groups, is the textbook demonstration that a peptide can be orally absorbed when enough of its amide N–H groups are masked. The dedicated treatment is What Is N-Methylation.

D-amino acids are the mirror images of the natural L residues. Because peptidase active sites are themselves chiral, a D-residue at or near the cleavage site frequently will not fit, so the bond survives. Substituting D-residues — or scanning a sequence one position at a time to find where a D-residue is tolerated — is one of the oldest stabilising tactics, and it underlies the retro-inverso design described later. The broader chemistry of handedness is the subject of D-Amino Acids in Peptides.

Peptoids: side chains on the nitrogen

A peptoid is a peptidomimetic in which every side chain is moved from the alpha-carbon to the backbone nitrogen, turning the polymer into an oligomer of N-substituted glycines. That one structural shift removes the backbone N–H across the whole chain and makes peptoids strongly resistant to proteases.

Peptoids were introduced in 1992 as a modular approach to drug discovery, with the key insight that moving the side chain onto the nitrogen preserves the overall spacing of functional groups while eliminating the amide hydrogens that both invite proteolysis and hinder permeability.^[7] Their practical appeal comes from how they are built: the submonomer method, published the same year, assembles each residue from two cheap, widely available reagents — a haloacetic acid and a primary amine — rather than from a pre-made protected amino acid, so an enormous range of side chains can be installed without custom building blocks.^[8] Because the side chain sits on the nitrogen rather than a stereocentre at the alpha-carbon, simple peptoids are also achiral at the backbone, which simplifies their synthesis even as it changes how they fold.

β-peptides and foldamers

β-peptides and related oligomers belong to a larger idea called foldamers: synthetic chains that are not natural peptides but still fold into predictable, repeating shapes. They mimic peptides at the level of secondary structure rather than single bonds.

The term foldamer was framed by Gellman in a 1998 account as any oligomer that folds into a conformationally ordered state in solution, with interactions between non-adjacent units.^[9] The best-studied examples are β-peptides, built from β-amino acids that carry one extra backbone carbon per residue. That extra methylene gives the chain more rotatable bonds, yet β-peptides form helices that are, if anything, more robust than those of ordinary α-peptides, and particular ring-constrained β-residues steer the chain toward specific helix geometries.^[1][10] Crucially, the enzymes that cut natural peptides do not recognise the β-backbone, so these foldamers are highly stable in biological settings. A 2001 review traces how β-peptide structure was worked out and then put to functional use, and the same foldamer principle extends to γ-peptides and mixed backbones.^[10]

Azapeptides, depsipeptides and retro-inverso chains

Several further classes modify the backbone in defined ways while still looking, at a glance, like a chain of residues. Each changes one aspect of the peptide bond or the chain direction.

An azapeptide replaces the alpha-carbon of a residue with a nitrogen atom, so that a hydrazine-derived unit sits in the chain; this flattens the local geometry and changes how the neighbouring bonds behave, and such units are made by acylating hydrazines rather than amino acids.^[1] A depsipeptide swaps one or more amide bonds for ester bonds, replacing an N–H link with an oxygen link; many natural products are depsipeptides, and the substitution removes a hydrogen-bond donor and a protease recognition point.

A retro-inverso peptide is a more radical rearrangement: the sequence is reversed and every residue is switched to the D configuration. The combination is designed so that the side chains end up in roughly the same positions as in the parent peptide, while the backbone runs in the opposite direction and resists proteases. Chorev and Goodman’s 1993 account, “A dozen years of retro-inverso peptidomimetics,” lays out both the appeal and the limits of the strategy — notably that reversing the chain changes the direction of the backbone hydrogen bonds, so a retro-inverso analogue mimics its parent well only when side-chain contacts, not backbone contacts, dominate the binding.^[11] The relationship to ring-closed designs is covered in Cyclic Peptides Explained.

Mimicking a whole shape: helices, turns and sheets

The most ambitious peptidomimetics reproduce an entire element of a protein’s folded structure — a helix, a turn or a sheet — so that they can interfere with the large, flat interfaces where proteins bind one another. These are the Type III, scaffold-based mimetics.

α-Helix mimetics aim to present the handful of side chains that project from one face of a helix. Approaches range from reinforcing a real peptide helix, as in hydrocarbon stapling, to replacing it entirely with a rigid organic scaffold; Hamilton’s terphenyl framework, from the early 2000s, was an influential early example of the scaffold route.^[1] Hydrocarbon stapling, in which a synthetic bridge is built across one turn of a helix to lock it in shape and shield it from proteases, is treated on its own in What Is Peptide Stapling, and a 2014 review sets out its principles and progress.^[14] β-Turn mimetics use turn-inducing elements — D-proline, the quaternary residue Aib, or small-molecule templates — to reproduce the tight reversal where a chain changes direction, and β-sheet mimetics use constrained building blocks and flat scaffolds to hold two strands in register.^[1]

Peptidomimetics that became drugs

Peptidomimetics are not a theoretical exercise: several of the most important drug classes of the late twentieth century were peptidomimetics, and their histories show the approach working end to end. The common thread is a peptide lead rebuilt into a stable, often orally active molecule.

Captopril is the founding example. In the 1960s, Sérgio Ferreira found that peptides in the venom of the Brazilian pit viper Bothrops jararaca potentiated bradykinin and inhibited angiotensin-converting enzyme; one of them, a nine-residue peptide, was developed by Miguel Ondetti and David Cushman at Squibb into teprotide, which lowered blood pressure but had to be injected and was impractical as a medicine.^[16] Reasoning from a model of the enzyme’s active site, the Squibb team kept the chemical features that bound the enzyme and discarded the peptide chain, arriving at captopril — a small, orally active molecule that reached the market in 1981 and is remembered as a landmark of rational, structure-based design.^[12][15] Enalaprilat and lisinopril followed from the same line of work.^[1]

The HIV-1 protease inhibitors are the other canonical case. HIV protease cleaves viral polyproteins at peptide bonds, so inhibitors were built around transition-state isosteres — chiefly the hydroxyethylamine motif — that resemble the intermediate of that cleavage and bind the enzyme far more tightly than its natural substrate.^[1][13] A 1998 review describes this programme as a major success of structure-assisted drug design, and the resulting medicines transformed the treatment of HIV.^[13] The renin inhibitor aliskiren, built on a hydroxyethylene transition-state motif, extends the same logic to another peptide-cleaving enzyme.^[1] For how approved peptide and peptide-derived medicines developed over a century, see A History of Peptide Drugs.

How peptidomimetics are built and checked

Most peptidomimetics are assembled by the same solid-phase methods used for ordinary peptides, adapted for their unusual building blocks, and they are verified by the same analytical tools. The chemistry changes; the quality questions do not.

Peptoids, β-peptides and backbone-modified chains are generally made on resin, one unit at a time, as in standard synthesis; peptoids are the clear exception in that their submonomer route builds each residue in place from two reagents rather than coupling a pre-formed monomer.^[8] Non-peptide scaffold mimetics are made by conventional organic synthesis instead. Whichever route is used, the finished molecule is characterised the way any synthetic compound is: its identity is confirmed by mass spectrometry, which reads the mass shift that each modification introduces, and its purity is measured by reversed-phase HPLC. The general manufacturing picture is set out in What Is Solid-Phase Peptide Synthesis, and the same side reactions, isomers and related substances that complicate ordinary peptides apply, often in new forms, to their mimetics.

Peptide, peptidomimetic and small molecule

A peptidomimetic occupies the middle of a spectrum that runs from a natural peptide at one end to a conventional small-molecule drug at the other, and the point of the category is to combine the best of both. The table below summarises the trade-offs that motivate the design.

The line between the three is not sharp, which is the whole point: a peptidomimetic is defined by its intent — to reproduce a peptide’s action — rather than by a fixed chemical rule, so individual molecules can sit anywhere along the spectrum. The related question of where peptides end and other molecule types begin is explored in Peptide vs Drug vs Biologic.

What this guide does not establish

This is an educational account of a chemistry concept and its history. A few limits are worth stating directly.

• It describes a design strategy, not a product line. Peptidomimetics are a broad class in the research literature; naming the strategy says nothing about what any particular catalogue item is or how it is classified.
• The drug examples are history, not endorsements. Captopril, the HIV protease inhibitors and aliskiren are approved medicines discussed to illustrate how the approach developed; nothing here describes their use, and they are not research compounds.
• Stability and permeability are design goals, not guarantees. Whether a given modification actually improves a molecule is an empirical question answered case by case, not a property that follows automatically from the class.
• Nothing here concerns use in a person or animal. The guide covers molecular design and analysis only; it does not describe dosing, administration or outcomes.
• Nothing here describes where any compound is synthesised. The synthesis methods are general chemistry and are not a statement about the origin of any specific material.

Frequently asked questions

What is a peptidomimetic?

A peptidomimetic is a molecule designed to reproduce a peptide’s shape and biological action while shedding the weaknesses that limit peptides, such as rapid breakdown by enzymes, poor membrane crossing and a short lifetime in solution. It keeps the peptide’s pharmacophore, the arrangement of features a target recognises, but rebuilds the backbone or side chains into something more stable and more drug-like.

What is the difference between a peptide and a peptidomimetic?

A peptide is a chain of amino acids joined by ordinary amide (peptide) bonds. A peptidomimetic deliberately departs from that chemistry: it may replace some peptide bonds with other linkers, move the side chains onto the nitrogen, lengthen the backbone, flip residues to the mirror-image D form, or drop the amino-acid chain entirely in favour of a rigid scaffold that holds the same groups in the same positions. The goal is to keep the function while changing the chemistry.

Why are peptidomimetics used instead of peptides?

Natural peptides have practical weaknesses as molecules: proteases cut them quickly, they cross membranes poorly, they are cleared fast, and their flexible chains can bind more than one target. Peptidomimetics are built to overcome these liabilities, by resisting enzymes, holding a single rigid shape and behaving more like a conventional small-molecule drug, while preserving the binding features that made the original peptide active.

What is a peptoid?

A peptoid is a peptidomimetic class in which each side chain is attached to the backbone nitrogen rather than to the alpha-carbon, making the polymer an oligomer of N-substituted glycines. Moving the side chain removes the backbone N-H, which takes away a hydrogen-bond donor and makes peptoids resistant to proteases. They were introduced in 1992 and are assembled by a submonomer method that builds each unit from two simple reagents.

What are the main types of peptidomimetics?

One common scheme sorts them by how much peptide character remains: local changes to a single bond or residue; backbone replacements such as peptoids, beta-peptides and other foldamers; and non-peptide scaffolds that carry the key groups on a rigid framework with no amino-acid chain at all. An older scheme labels them Type I (mimics of the local backbone), Type II (small molecules that act at the same site), and Type III (scaffolds that reproduce a whole secondary structure).

Is a peptidomimetic a peptide or a small molecule?

It can sit anywhere on the line between the two. Some peptidomimetics are almost entirely peptide with one modified bond; others are effectively small molecules that happen to mimic a peptide’s binding surface. The term describes the design intent, reproducing a peptide’s action, rather than a fixed chemical category.

Are peptidomimetics more stable than peptides?

That is usually the point of making one. Replacing peptide bonds with enzyme-resistant linkers, moving side chains onto the nitrogen, or substituting D-amino acids all make a molecule harder for proteases to recognise and cut, which extends how long it survives. Stability is only one of several goals, alongside membrane permeability and holding a single defined shape.

Is captopril a peptidomimetic?

Yes. Captopril, an angiotensin-converting-enzyme inhibitor, is one of the classic peptidomimetics. It grew out of teprotide, a nine-amino-acid peptide from pit-viper venom that inhibited the enzyme but was not orally active. Chemists at Squibb kept the features that bound the enzyme’s active site and rebuilt the rest into a small, orally active molecule, which launched in 1981. The HIV protease inhibitors and the renin inhibitor aliskiren came from the same transition-state-mimicking approach.

References

1. Lenci, E., & Trabocchi, A. (2020). Peptidomimetic toolbox for drug discovery. Chemical Society Reviews, 49(11), 3262–3277. doi:10.1039/D0CS00102C
2. Avan, I., Hall, C. D., & Katritzky, A. R. (2014). Peptidomimetics via modifications of amino acids and peptide bonds. Chemical Society Reviews, 43(10), 3575–3594. doi:10.1039/C3CS60384A
3. Pelay-Gimeno, M., Glas, A., Koch, O., & Grossmann, T. N. (2015). Structure-Based Design of Inhibitors of Protein–Protein Interactions: Mimicking Peptide Binding Epitopes. Angewandte Chemie International Edition, 54(31), 8896–8927. doi:10.1002/anie.201412070
4. Vagner, J., Qu, H., & Hruby, V. J. (2008). Peptidomimetics, a synthetic tool of drug discovery. Current Opinion in Chemical Biology, 12(3), 292–296. doi:10.1016/j.cbpa.2008.03.009
5. Giannis, A., & Kolter, T. (1993). Peptidomimetics for Receptor Ligands—Discovery, Development, and Medical Perspectives. Angewandte Chemie International Edition in English, 32(9), 1244–1267. doi:10.1002/anie.199312441
6. Hruby, V. J. (2002). Designing peptide receptor agonists and antagonists. Nature Reviews Drug Discovery, 1(11), 847–858. doi:10.1038/nrd939
7. Simon, R. J., Kania, R. S., Zuckermann, R. N., et al. (1992). Peptoids: a modular approach to drug discovery. Proceedings of the National Academy of Sciences, 89(20), 9367–9371. doi:10.1073/pnas.89.20.9367
8. Zuckermann, R. N., Kerr, J. M., Kent, S. B. H., & Moos, W. H. (1992). Efficient method for the preparation of peptoids [oligo(N-substituted glycines)] by submonomer solid-phase synthesis. Journal of the American Chemical Society, 114(26), 10646–10647. doi:10.1021/ja00052a076
9. Gellman, S. H. (1998). Foldamers: A Manifesto. Accounts of Chemical Research, 31(4), 173–180. doi:10.1021/ar960298r
10. Cheng, R. P., Gellman, S. H., & DeGrado, W. F. (2001). β-Peptides: From Structure to Function. Chemical Reviews, 101(10), 3219–3232. doi:10.1021/cr000045i
11. Chorev, M., & Goodman, M. (1993). A dozen years of retro-inverso peptidomimetics. Accounts of Chemical Research, 26(5), 266–273. doi:10.1021/ar00029a007
12. Cushman, D. W., & Ondetti, M. A. (1991). History of the design of captopril and related inhibitors of angiotensin converting enzyme. Hypertension, 17(4), 589–592. doi:10.1161/01.HYP.17.4.589
13. Wlodawer, A., & Vondrasek, J. (1998). Inhibitors of HIV-1 Protease: A Major Success of Structure-Assisted Drug Design. Annual Review of Biophysics and Biomolecular Structure, 27, 249–284. doi:10.1146/annurev.biophys.27.1.249
14. Walensky, L. D., & Bird, G. H. (2014). Hydrocarbon-Stapled Peptides: Principles, Practice, and Progress. Journal of Medicinal Chemistry, 57(15), 6275–6288. doi:10.1021/jm4011675
15. Pharmaceutical Journal (2016). From snake venom to ACE inhibitor — the discovery and rise of captopril. https://pharmaceutical-journal.com/article/news/from-snake-venom-to-ace-inhibitor-the-discovery-and-rise-of-captopril
16. Teprotide. Wikipedia. https://en.wikipedia.org/wiki/Teprotide

To go deeper on the chemistry behind these designs, see What Is N-Methylation, D-Amino Acids in Peptides and What Is Peptide Stapling; for how stability is engineered, see Peptide Half-Life Extension; and for where peptides sit among other molecule types, see Peptide vs Drug vs Biologic.

All Patriot Labs products are sold strictly for in-vitro research and laboratory use only. Not for human or veterinary consumption. This guide is educational and describes the chemistry and history of peptidomimetics in general terms; it is not medical advice, does not describe how to use any product, and makes no claim about any specific product or its manufacturing location.